신원보존술의 임상적 적응

박철보,강주석,이창규,류현열 고신대학교(의대) 고신대학교 의과대학 학술지 2002 고신대학교 의과대학 학술지 Vol.17 No.1

Background : The presenting study was undertaken to evaluate the efficacy of nephron sparing surgery in the management of benign renal lesion and renal cell carcinoma, with respect to the preservation of renal function and absence of tumor recurrence. Methods : From 1985 to 1999, 35 patients underwent nephron sparing surgery for treatment. The clinical presentation, clinical diagnosis, surgical approach, outcome and complication in these patients were analyzed. Surgical treatment for renal tumor was performed in a single, small (<4cm), well localized, unilateral renal tumor with normal contralateral kidney except imperative case. Results : The diagnosis of study population were composed of renal stone (5 cases), renal tuberculosis (3 cases), renal rupture (5 cases), double pelvis (2 cases), calyceal diverticulum (2 cases), partial hydronephrosis (3 cases) and renal tumor (15 cases). The postoperative biopsy results of renal tumors were renal cell carcinoma (7 cases), angiomyolipoma (5 cases), complicated cyst (2 cases), and renal pelvic cancer (1 case). The surgical methods of nephron sparing procedure were chosen according to tumor location and surgeons' preference. Partial nephrectomy was performed in 24, enucleation in 8 and wedge resection in 3. The case of renal pelvic cancer was metastatic cancer from contralateral kidney. The mean amount of intraoperative and postoperative bleeding was 430 cc. The postoperative complications were observed in 4 cases (hematoma in 1, urinary fistula in 3 cases) and no nephrectomy due to complication was undergone. There was no change in postoperative renal function and no patient required acute hemodialysis following nephorn sparing surgery. The overall mean postoperative follow-up in renal cell carcinoma was 39.4 (10-140) months. There was no evidence of local recurrence till this study was completed after nephron sparing surgery. Conclusion : Nephron sparing surgery is a viable treatment option not only in benign renal lesion but also in localized small cell carcinoma.

신원보존술의 임상적 적응

박철보,강주석,이창규,류현열 고신대학교 의학부 2002 高神大學校 醫學部 論文集 Vol.17 No.1

Background The presenting study was undertaken to evaluate the efficacy of nephron sparing surgery in the management of benign renal lesion and renal cell carcinoma, with respect to the preservation of renal function and absence of tumor recurrence. Methods From 1985 to 1999, 35 patients underwent nephron sparing surgery for treatment. The clinical presentation, clinical diagnosis, surgical approach, outcome and complication in these patients were analyzed Surgical treatment for renal tumor was performed in a single, small (<4㎝). well localized, unilateral renal tumor with normal contralateral kidney except imperative case. Results The diagnosis of study population were composed of renal stone (5 cases), renal tuberculosis (3 cases), renal rupture (5 cases), double pelvis (2 cases), calyceal diverticulum (2 cases), partial hydronephrosis (3 cases) and renal tumor (15 cases). The postoperative biopsy results of renal tumors were renal cell carcinoma (7 cases), angiomyolipoma (5 cases), complicated cyst (2 cases), and renal pelvic cancer (1 cases). The surgical methods of nephron sparing procedure were chosen according to tumor location and surgeon's preference. Partial nephrectomy was performed in 24, enucleation in 8 and wedge resection in 3. The case of renal pelvic cancer was metastatic cancer from contralateral kidney. The mean amount of intraoperative and postoperative bleeding was 430cc. The postoperative complications were observed in 4 cases (hematoma in 1, urinary fistula in 3 cases) and no nephrectomy due to complication was undergone. There was no change in postoperative renal function and no patient required acute hemodialysis following nephron sparing surgery. The overall mean postoperative follow-up in renal cell carcinoma was 39.4 (10-140) months. There was no evidence of local recurrence till this study was completed after nephron sparing surgery. Conclusion Nephron sparing surgery is a viable treatment option not only in benign renal lesion but also in localized small cell carcinoma.

Rapamycin/Paclitaxel이 사람과 흰쥐 평활근세포에서 Heme oxygenase-1의 발현에 미치는 영향

박철보,정헌택,류현열 고신대학교(의대) 고신대학교 의과대학 학술지 2005 고신대학교 의과대학 학술지 Vol.20 No.1

Background : Both rapamycin and paclitaxel are currently being used in drug-eluting stent to block the proliferation of vascular endothelial and smooth muscle cells. Heme oxygenase-1 (HO-1) has also known to be anti-proliferative against vascular cells. In this study, it focused on the role of HO-1 in cytoprotection and antiproliferation of paclitaxel. Methods : Proliferation of cells and metabolic activity of HO-1 were evaluated with the tetrazolium-based assay. HO-1 protein expression was shown by western blot analysis of vascular smooth muscle cells (VSMCs), or endothelial cells (ECs), using anti-HO-1 polyclonal antibody from untreated cells and cells exposed to rapamycin and paclitaxel. To determine whether the inhibition of paclitaxel on platelet-derived growth factor (PDGF)-dependent proliferation may be mediated by its induction of HO-1 we exposed cells to paclitaxel, PDGF and ZnPP, an inhibitor of HO activity. Survival rate was checked to find the anti-apoptotic effect of paclitaxel against tumor necrosis factor (TNF)-a-mediated apoptosis, in the presence or abscence of ZnPP. Result : Rapamycin induces HO-1 protein in rat VSMCs and human ECs. Exposure of VSMCs to paclitaxel for 12h resulted in a dose-dependent increase in HO-1 ativity. Ten nM of paclitaxel led to a maimal expression of HO-1 protein at 12h after exposure. The addition of ZnPP abrogated the suppression effect of paclitaxel on PDGF-stimulated cell proliferation, and blocked paclitaxel-mediated suppression of TNF-a-mediated apoptosis. Hemoglobin, a scavenger of CO, abrogated the paclitaxel induced cytoprotection. Conclusion : Paclitaxel induced the expression of HO-1 gene in rat VSMCs and human ECs, in dose-dependent and time-dependent manner, like rapamycin.

Induction of Heme Oxygenase-1 Expression by Rapamycin and Paclitaxel in Smooth Muscle and Endothelial Cells of Human and Rat

Park, Chul Bo,Chung, Hun Taeg,Rhew, Hyun Yul 고신대학교 의학부 2005 高神大學校 醫學部 論文集 Vol.20 No.1

Background: Both rapamycin and paclitaxel are currently being used in drug-eluting stent to block the proliferation of vascular endothelial and smooth muscle cells. Heme oxygenase-1 (HO-1) has also known to be anti-proliferative against vascular cells. In this study, it focused on the role of HO-1 in cytoprotection and antiproliferation of paclirtaxel. Methods: Proliferation of cells and metabolic activity of HO-1 were evaluated with the tetrazolium-based assay. HO-1 protein expression was shown by western bolt analysis of vascular smooth muscle cells (VMSCs), or endothelial cells (ECs), using anti-HO-1 polyclonal antibody from untreated cells and cells exposed to rapamycin and paclitaxel. To determine whether the inhibition of paclitaxel on platelet-derived growth factor (PDGF)-detpendent proliferation may be mediated by its induction of HO-1, we exposed cells to paclitaxel, PDGF and ZnPP, an inhibitor of HO activity. Survival rate was checked to fine the anti-apototic effect of paclitaxel against tumor necrosis factor (TNF)-α-mediated apoptosis, in the presence or abscence of ZnPP. Result: Rapamycin induces HO-1 protein in rat VSMCs and human ECs. Exposure of VSMCs to palcitaxel for 12 h resulted in a dose-dependent increase in HO-1 activity. Ten nM of paclitaxel led to a maximal expression of HO-1 protein at 12h after exposure. The addition of Znp abrogated the suppression effect of paclitaxel on PDGF-stimulated cell proliferation, and blocked paclitaxel-mediated suppression of TNF-α mediated apoptosis. Hemoglobin, a scavenger of CO, abrogated the paclitaxel induced cytoprotection. Conclusion: Paclitaxel induced the expression of HO-1 gene in rat VSMCs and human ECs, in dose-dependent and time dependent manner, like rapamycin.

수술중 우연히 발견된 소아 고환기형종 1례

안성수,박철보,이융휘,장양일,오경준,김규환 大韓泌尿器科學會 1996 Korean Journal of Urology Vol.37 No.5

무정자증을 동반한 XYY 증후군 1례

이준용,박철보,이융휘,오경준,김규환 大韓泌尿器科學會 1994 Korean Journal of Urology Vol.35 No.2